Skip to main
CBLL

Ceribell Inc (CBLL) Stock Forecast & Price Target

Ceribell Inc (CBLL) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CeriBell is an innovative MedTech company that has developed the Ceribell System, a novel point-of-care electroencephalography (EEG) platform designed to rapidly diagnose and continuously monitor patients with neurological conditions. With a proprietary AI-driven algorithm, the company offers a unique product for the diagnosis of Electrographic Status Epilepticus, and has recently expanded its indication to include pediatrics and neonates. With a strong commercialization strategy and a pipeline of new products, along with a healthy financial profile and rapid growth trajectory, CeriBell presents an attractive investment opportunity.

Bears say

CeriBell is a medical technology company with a promising product portfolio, but there are several concerns that could hinder its success. These include slow contracting timelines for its Ceribell System, potential for increased tariffs on imports from China, and an outlier in a survey of physicians who reported a drop-off in use of the system with no explanation. The company's focus on delirium monitoring and its goal of achieving cash flow breakeven with cash on hand are positive factors, but there are still risks to consider in investing in this stock.

Ceribell Inc (CBLL) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ceribell Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ceribell Inc (CBLL) Forecast

Analysts have given Ceribell Inc (CBLL) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Ceribell Inc (CBLL) has a Strong Buy consensus rating as of Sep 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ceribell Inc (CBLL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.